申请人:THE BROAD INSTITUTE, INC.
公开号:US20150284371A1
公开(公告)日:2015-10-08
This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can be used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections. The compounds have the formula: wherein R
1
and R
2
are independently H, halogen, cyano, haloalkyl, haloalkyloxy or OMe; or R
1
and R
2
together are —O—CH
2
— or -0- CF
2
—O—; R
3
is H, halogen, cyano, haloalkyl or haloalkyloxy; R
4
is C
1-6
alkyl, C
3-6
cycloalkyl, C
3-6
cycloalkylmethyl or C
3-6
cycloheteroalkyl, wherein the heteroatom is N or 0; R
5
is H or CH
3
; R
6
is C
1-6
alkyl or C
3-6
cycloalkyl; and A, B, D and E are each, independently, CH, N, 0 or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, 0 or S.
该申请描述了一种可以抑制清道夫受体B类,类型I(SR-BI)活性的化合物和方法,这些化合物和方法可以用于介导高密度脂蛋白(HDL)脂质摄取和治疗丙型肝炎病毒感染。这些化合物的化学式为:其中R1和R2独立地为H,卤素,氰基,卤代烷基,卤代烷氧基或OMe;或者R1和R2在一起为—O—CH2—或-0-CF2—O—;R3为H,卤素,氰基,卤代烷基或卤代烷氧基;R4为C1-6烷基,C3-6环烷基,C3-6环烷基甲基或C3-6环杂烷基,其中杂原子为N或O;R5为H或CH3;R6为C1-6烷基或C3-6环烷基;而A、B、D和E分别独立地为CH、N、O或S,其中至少一个为N,另一个为N、O或S。